In silico Experimentation of Glioma Microenvironment Development and Anti-tumor Therapy

Yu Wu¹, Yao Lu¹, Weiqiang Chen², Jianping Fu², Rong Fan¹,³,⁴

¹Department of Biomedical Engineering, Yale University, New Haven, Connecticut, United States of America, ²Department of Mechanical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America, ³Human and Translational Immunology Program, Yale University, New Haven, Connecticut, United States of America, ⁴Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut, United States of America

Abstract

Tumor cells do not develop in isolation, but co-evolve with stromal cells and tumor-associated immune cells in a tumor microenvironment mediated by an array of soluble factors, forming a complex intercellular signaling network. Herein, we report an unbiased, generic model to integrate prior biochemical data and the constructed brain tumor microenvironment in silico as characterized by an intercellular signaling network comprising 5 types of cells, 15 cytokines, and 69 signaling pathways. The results show that glioma develops through three distinct phases: pre-tumor, rapid expansion, and saturation. We designed a microglia depletion therapy and observed significant benefit for virtual patients treated at the early stages but strikingly no therapeutic efficacy at all when therapy was given at a slightly later stage. Cytokine combination therapy exhibits more focused and enhanced therapeutic response even when microglia depletion therapy already fails. It was further revealed that the optimal combination depends on the molecular profile of individual patients, suggesting the need for patient stratification and personalized treatment. These results, obtained solely by observing the in silico dynamics of the glioma microenvironment with no fitting to experimental клинического data, reflect many characteristics of human glioma development and imply new venues for treating tumors via selective targeting of microenvironmental components.

Copyright: © 2012 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by the US National Cancer Institute Howard Temin Pathway to Independence Award (NIH R00 CA136759-02, PI: R.F.), the US National Science Foundation (CMMI 1129611) (PI: J.F.) and partly by the Bill & Melinda Gates Foundation Grand Challenges Explorations Award (round 4 PI: R.F.). Y.W. is supported by the Anderson Postdoctoral Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Tumor cells and stromal cells actively “talk” to each other via an array of soluble signaling molecules, leading to co-evolution of the tumor and its microenvironment [1,2,3,4,5]. This also implies that the tumor microenvironment itself is a critical aspect of disease mechanism and that the microenvironmental components, including cells and soluble mediators, may represent a new set of targets for anti-tumor therapy [6,7,8,9]. However, due to the inherent heterogeneity of the tumor microenvironment and the complexity of the cell-cell communication network, it remains poorly understood at the system level how these cells and their communication network collectively shape a heterogeneous tumor microenvironment and modulate tumorigenesis and metastasis. Conventional approaches that examine one or two selected pathways are incapable of fully assessing complex signaling networks and recapitulate the dynamics of the tumor microenvironment, and often result in contradictory conclusions. Thus, systems approach that examines various cell types and the associated intercellular signaling networks in the tumor microenvironment is highly desired.

In this work we choose to study the dynamics of glioblastoma multiforme (GBM) development. GBM is one of the most malignant brain tumors, with conventional therapies against “common” oncogenic targets usually ineffective due in part to the high degree of tumor heterogeneity. Astrocytes, microglia, and infiltrating immune cells actively interact with glioma and glioma stem cells via complex intercellular signaling networks mediated by an array of soluble signaling molecules, e.g., cytokines, growth factors, and neuropoietin [10]. All these collectively shape a tumor microenvironment that could be distinct from one patient to another. Despite substantial research efforts and significant advances in cancer therapeutics, human GBM remains the most aggressive and lethal brain tumor in humans. In addition to inter-tumoral and inter-patient heterogeneity, GBM also exhibits significant intra-tumoral heterogeneity down to the single-cell level [11,12]. First, glioma cells originate from a variety of dynamically evolving progenitor cells [13]. It has been demonstrated that GBM cells demarcated by the neural stem cell marker CD133 exhibit much enhanced competencies for self-renewal and tumor initiation [14,15]. Recent studies have also shown instances in which CD133-negative cells were able to generate the same outcomes [16,17,18,19]. Second, glioma cells constantly interact with a variety of stromal cells. There is evidence that glioma cells acquire the ability to recruit and subvert their untransformed neighbor microglia into active collaborators to facilitate tumorigenesis. Direct correlation has been reported between the grade of glioma and the level of resident tumor microglia [20], suggesting the mutual paracrine stimulation between microglial cells and glioma cells [21,22,23,24]. Microglial cells recruited by glioma can

Citation: Wu Y, Lu Y, Chen W, Fu J, Fan R (2012) In silico Experimentation of Glioma Microenvironment Development and Anti-tumor Therapy. PLoS Comput Biol 8(2): e1002355. doi:10.1371/journal.pcbi.1002355

Editor: Greg Tucker-Kellogg, National University of Singapore, Singapore

Received July 25, 2011; Accepted December 4, 2011; Published February 2, 2012

E-mail: rong.fan@yale.edu
Promote tumor growth [25,26,27], dictated by paracrine loops responsible for glioma initiation and progression (e.g., IL-6, IL-10, TGF-β, prostaglandins, G-CSF, and GM-CSF, and growth factors such as EGF, VEGF, HGF, and SCF). The cross-talk between activated astroglial and glioma cells has also been documented, although the mechanism of their interactions has not been fully revealed. For example, astroglial cells produce IL-1β [28,29] that promotes cell proliferation [30,31,32] and tumor angiogenesis [33,34,35]. Upon stimulation by the autocrine IL-1β these cells further secrete TNF-α and IL-6 [36,37,38]. The former was found to increase VEGF [39], EGF receptor [40], and MMP-9 [41] expression in glioma cells, suggesting that astroglia-produced cytokines may influence all the three most critical aspects of glioma cell survival: angiogenesis (VEGF), proliferation (EGFR), and migration (MMP-9).

In silico models of tumor microenvironment integrate information about the biological context in which cancers develop, and thus represent a multi-scale consideration of oncogenesis as it occurs within somatic tissues [42,43]. Multiple factors involved in the development of an intrinsically complex tumor microenvironment have been studied including extracellular molecules, a spatially intricate and dynamic vasculature, and the immune system. Thus far, these models can be broadly divided into ‘continuum’ models, and discrete or ‘agent-based’ models as summarized in a review by Price and coauthors [43]. The latter describe the dynamics of individual interacting units, such as cancer cells, in small confined space; the former can be applied to a large tissue scale where agent-based modeling is computationally prohibitive. However, none of these methods have been integrated with a large cell-cell communication network in a complex tumor microenvironment. Herein we integrate all the intercellular signaling pathways known to date for human glioblastoma, as shown in the diagram of Fig. 1a. Five types of cells – quiescent and activated glioma initiating/progenitor cells, glial cells, and astroglial and microglial cells – and a panel of 15 growth factors/cytokines/chemokines were included in the signaling network. Then we derived a quantitative model using stochastic population dynamics and the Hill functions. First, a basic population dynamic equation was employed to compute the growth rate of five cell types as a function of their proliferation rate, decay/apoptosis rate, the rate of formation via direct mutation, the rate of formation via differentiation of their stem/progenitor cells, and the rate of dedifferentiation. Second, the temporal growth rate of each cell type is also modulated by soluble signaling mediators present in the tumor microenvironment; this process is quantitatively described by the Hill functions. All differential equations are described in Supporting Text S1 and the initial settings of all parameters are detailed in Supporting Table S1. As an example, we present here the procedure on how to construct the model for glioma cell population. It has been suggested that glioma can originate from cells at multiple differentiation stages during glial cell development, whereas the progenitor cells appear to be more susceptible to neoplastic transformation compared with mature glial cells [46,47]. Cytokine signalings, including IL-1, IL-6, IL-10, TGF-β, EGF, VEGF, HGF, G-CSF, SCF, and MIF, participate in the mechanism of promoting GBM growth. PGE2 can transiently prevent glioma cell proliferation in vitro. EGF, FGF, and MIF are predominantly survival factors for GBM cells. To re-illustrate the underlying physics of this model, we show the population dynamics for glioma cells as in equation 1, which integrate all the above signalings:

\[
\frac{dc_{glioma}}{dt} = \frac{d_{differentiation}H_2(VEGF,F,I) - d_{mutation}H_1(EGF) + d_{initiation}}{d_{proliferation}L(c_{glioma},c_{ASC}) + d_{angiogenesis}A_{angiogenesis}} - d_{decay}H_4(c_{glioma},c_{FGF},c_{SCF})
\]

where \( c_{cell/cytokine} \) is the concentration of cell/cytokine, \( f \) is the basal rate function, \( H_1, H_2, H_3, H_4, \) and \( H_5 \) are Hill functions, \( L \) is a logistic function, and \( A_{angiogenesis} \) is defined as the angiogenesis factor. Similarly, the same algorithm was applied to derive population dynamics equations for other cells. More details may be found in Method and the sections 1&2 in Supporting Text S1.

The change of cytokines associated with tumor microenvironment development is described as the production and consumption by all the cells and modulation by other cytokines as revealed by prior experiments. For example, glioma stem cells, glioma cells, and microglial cells secrete substantial amounts of VEGF. MIF and TNF-α have been observed to induce a significant dose-dependent increase of VEGF. The dynamics of VEGF is thus governed by a differential equation (Eq. 10) related to these cells and soluble mediators:
Dynamics of glioma cells, glioma stem cells, astrocytes, and microglial cells

We performed an \textit{in silico} stochastic study of glioma microenvironment development in a 1-ml control volume over a period of 12 months and observed a non-linear, synergistic co-evolution of all five cell types (Fig. 1b–f). The dynamics of glioma cells (GC) exhibit three distinct phases (Fig. 1b): the pre-tumor phase (1–5 months), the rapid expansion phase (6–10 months), and the malignant phase that corresponds to semi-steady high-grade glioblastoma (11–12 months). The starting cell populations are astrocyte \((2.8 \times 10^7/\text{ml})\), microglia \((2 \times 10^6/\text{ml})\), and quiescent stem cells \((QSC) (1 \times 10^4/\text{ml})\). The initial conditions only change the quantitative timeline of the dynamics but would not affect the general trends observed in our model that properly reflect the dynamics of human glioma (see Supporting Fig. S2). The number of glioma cells at \(t = 0\) is zero, and glioma cells develop via either neoplastic transformation of normal astrocyte or differentiation of glioma stem cells. The initial rate constants (time = 0) are derived from literature reports \([48,49]\), and become gradually subjected to the modulation by soluble factors (cytokines and growth factors). We observed that glioma stem cells are the major cell sources for glioma formation. At the early stage, QSCs upon stimulation are rapidly activated into activated stem cells (ASC) via a reversible process conferring self-renewal capability (Fig. 1c). This step proceeds to completion within the first month. Then both QSCs and ASCs stay at a relatively steady state over the next four
months before ASCs further differentiate into glioma cells in a stochastic manner. Despite the rapid lineage conversion of stem cells occurring as early as in the first month, glioma cells remain at a silent state with cell density way below the clinically detectable threshold. (For all the experiments shown here, the threshold for detecting glioma in the clinic is assumed to be \(1 \times 10^6\) cells/ml, which is in agreement with the data from clinical studies [50].) During the growth phase of glioma cells within the space that astrocytes occupy, astrocytes strive to maintain their abundance as well as their functions until they are displaced by the glioma cells in the late stage. The number of microglial cells follows a steady increase all the way from the pre-tumor to the malignant stage, with a small kink occurring at the onset of rapid tumor expansion (Fig. 1d).

Although no “clinical” signs are observed at the first phase, the imperceptible changes occurring in the tumor microenvironment silently accumulate tumorigenic signals and eventually result in a switch of fitness dominance between astrocyte and glioma. The glioma cells acquire competitive advantages and are primed to rapid growth within a month to reach the diagnostic threshold (\(\sim 1 \times 10^6\) cells/ml). This unique behavior is consistent with glioblastoma development observed in animal models [17]. It was assumed that after rapid expansion glioma cells follow a typical exponential growth mode in the next month until reaching a tumor cell concentration (\(\sim 1.5 \times 10^7\) cells/ml), and then gradually turn into a slow growth phase dictated by the logistic growth model [51,52]. The astrocyte population shrinks due to competitive selection pressure exerted by a microenvironment unfavorable to astrocyte proliferation or favorable to astrocyte apoptosis that decreases the fitness advantages over time and eventually causes the loss of dominance. We examined the contribution of direct mutation of astrocyte and the differentiation of glioma stem cells to glioma growth. We observed that neoplastic transformation of astrocytes directly to glioma cells does result in the formation of small numbers of glioma cells in the pre-cancer phase, but contributes little to tumor development in rapid growth and expansion phases (see Supporting Fig. S1). The total cell concentration experienced a significant expansion during the seventh month, suggesting a density-gradient-driven potential for the glioma cells to invade neighboring tissues (Fig. 1c). The total cell density we observed in the tumor microenvironment is higher than that in normal tissue, which is quantitatively consistent with the results obtained using tissue histology examinations [53,54,55]. A three-dimensional (3D) stochastic simulation (Fig. 1f) shows that the evolution of all the cell types and the time course are consistent with clinical glioblastoma development.

Cytokine dynamics and interaction

Cytokine dynamics also exhibit multi-stage non-linear characteristics (Fig. 2a). Activated microglial cells were found to be an important source of cytokines in the early stage, yielding a steady increase of cytokine concentrations prior to the emergence of tumor. These cytokines participate in the modulation of rapid glioma cell expansion in the later stage, suggesting that microglial cells may play an important role in tumor initiation by priming glioma cells at very low concentrations. Glioma cells also secrete paracrine signaling factors that promote the proliferation and migration of microglia, and thus in turn benefit from the increase of microglia cells that reside in the vicinity of the glioma growth front. The normalized dynamics curves (Fig. 2b) show that 15 cytokines fall into three categories according to their time traces. TNF-\(\alpha\) peaks at the end of the first phase, then gradually decreases presumably due to the consumption by glioma cells (e.g., rebind to TNF receptors and trigger the secondary signaling cascades); IL10 and PGE2 show a monotonic increase across all the three phases.

![Figure 2](https://example.com/figure2.png)

**Figure 2. Cytokine dynamics.** (a) Change of concentrations for all 15 cytokines in the microenvironment over a period of one year. (b) Normalized cytokine concentration change over a period of one year. It shows three types of cytokine dynamics based upon the temporal traces. TNF-\(\alpha\) peaks at the end of phase I. IL10 and PGE2 show constant increase regardless the growth phases of glioma cells. Other cytokines are apparently correlated to the three-phase growth dynamics. doi:10.1371/journal.pcbi.1002355.g002

All the other cytokines exhibit a rapid concentration increase in the second phase and reach a quasi-steady state correlated with the glioma population dynamics.

Therapy targeting the cells in the tumor microenvironment: microglia depletion

We first designed a novel therapy by targeting the cellular components of the tumor microenvironment. According to cell population dynamics (Fig. 1), microglial cells produce an array of cytokines that often prime glioma cells to predispose them to rapid population expansion in the sixth month, and thus function as a tumor-promoting factor in the tumor microenvironment. Therefore, we designed a cell-targeting therapy that eliminates microglial cells in the tumor microenvironment.

This therapy is realized by arbitrarily increasing the apoptotic rate of microglia by 10 times at the early, middle, and middle to late stages with the corresponding glioma cell density at \(5 \times 10^4\) cells/ml, \(2 \times 10^5\) cells/ml, or \(1 \times 10^6\) cells/ml, respectively. To examine the applicability of this therapy to patients with different biomolecular background and assess the effect of inter-patient heterogeneity on therapeutic response, three virtual patients with different profiles of initial parameters (cytokine production rate, receptor expression level, etc.) within the ranges reported in the literature [56] (Supporting Table S5) were treated using the same microglia depletion therapy at three different stages. The results are compared as shown in Fig. 3a–c. Two interesting features were observed in the microglia depletion therapy experiments. First, all patients responded in a similar manner although the length of therapeutic benefit and the recurrence time varied from one patient to the other. Second, the efficacy strongly depends on how early the treatment was given to the patients (Fig. 3d). All the patients treated at the early stage when glioma cell density (\(\sim 5 \times 10^7\) cells/ml) is far below the threshold for clinical tumor detection (\(1 \times 10^6\) cells/ml) showed no recurrence within the time of simulation. Treatment given at the early to middle stage (glioma cell density \(\sim 2 \times 10^6\) cells/ml) postpones the rapid tumor growth phase by two to four months and does give the patient therapeutic benefit. Patients treated right as the clinical sign emerges (glioma cell density \(\sim 1 \times 10^6\) cells/ml) did not respond at all in terms of glioma growth rate, suggesting that tumor cells have been fully primed and become self-sustained with no need of paracrine signaling to drive glioma cell proliferation. These results, obtained by unbiased integration of basic biochemical parameters and cell signaling processes, were found to appropriately reflect clinical and experimental observations.
There is a consensus that activated microglia promote glioma growth and promotion, which is consistent with our in silico glioma development experiments [20,39,40,41]. Recently, an animal model study indicated that clonal cooperation between different mutant cells can lead to tumor formation, whereas any single-cell type alone cannot develop into tumor [57]. What is more interesting is that the second clone, once activated by the first clone presumably through cytokine signaling, becomes fully self-sustained and develops into tumor without the presence of the first clone, which is strikingly similar to the glioma-microglia interaction observed in our model, and thus may share commonalities in molecular and cellular mechanisms. Our study suggests that cells in the tumor microenvironment can be good targets for therapeutic intervention or control of tumor progression, pointing to new venues for anti-tumor drug design and development.

Combination therapy targeting multiple cytokines

The results of microglia-depletion therapy indicate that patients do not show significant responses unless they are diagnosed at the very early stage—the time when no clinically detectable tumors have been formed. Thus, we turn to assess the possibility of combination therapy that directly targets a number of key cytokine signaling pathways, which is anticipated to give more focused and potent therapeutic effects.

Due to inter-tumoral heterogeneity, the best therapeutic regimen must be an individually tailored combination of inhibitors that act on selected cytokines or their receptors optimized for the patient. We performed a sensitivity analysis to assess the tumorigenic potential of each cytokine and find the primary targets that, once subjected to blockade or promotion, exhibit the most effective responses in therapeutic intervention. The Methods and section 3 in Supporting Text S1 describe the details of this analysis. Basically, it measures the length of time taken by glioma cells to grow from the threshold concentration (e.g., $1 \times 10^6$/ml) to an objective concentration (e.g., $1.5 \times 10^7$/ml) reflecting the survival time of a patient after the therapy is given. Twenty-nine tests, each perturbing a cytokine production rate or a cytokine receptor expression level, were performed to give the sensitivity factor of each cytokine or its receptor with respect to patient survival probability. According to the results, forced activation of a signaling pathway with a positive sensitivity factor is expected to promote patient survival, and vice versa. Individualized combination therapy is designed by enhancing the signaling processes of cytokines with the largest “positive” sensitivity factors and inhibiting those with the largest “negative” sensitivity factors. To test this therapy, the same virtual patients (patients 1, 2, and 3) that were randomly designed for microglia depletion experiments are examined here to generate sensitivity factor profiles for every patient (Fig. 4a). Next we designed a four-cytokine combination therapy.
therapy (VEGF, MIF, IL6, and HGF) optimized for patient 1, and all the patients were given the same treatment for comparison. First, we compared single-target therapy and combination therapy that are administered at the time of glioma cell density $1 \times 10^6$/ml (Fig. 4b and Supporting Fig. S3). Although each of the four cytokines has a large negative sensitivity factor for promoting tumorigenesis, therapies that inhibit only one of these cytokines can hardly alter the time course of tumor progress, due to the homeostatic robustness of the cytokine network and the resulting intrinsic resistance to perturbation. To overcome this issue, we further applied to virtual patient 1 a combination treatment that simultaneously inhibits all four cytokines, and we

Figure 4. Cytokine combination therapy. This was given to the same three virtual patients (Supporting Table S5) and administered at different stages, corresponding to glioma cell (GC) concentration $1 \times 10^6$/ml, $5 \times 10^6$/ml, $1 \times 10^7$/ml, and $2 \times 10^7$/ml, respectively. (a) Sensitivity analyses reveal the pro-tumorigenic potential of each cytokine in the examined tumor microenvironment. Supporting Table S7 summarizes all the parameters (u1–u29), surface receptor expression level. (b) Comparison of therapeutic efficacy between single-target and combination therapies. The combination therapy results in a striking synergistic effect to suppress tumor progression whereas any single target treatment does not show appreciable benefit. (c) Responses of three patients to the same combination therapy, which is tailored to give optimum response for patient 1 based upon sensitivity analysis. (d) Snapshots showing tumor development in patient 1 with or without combination therapy. The therapy is given at a single dose when the glioma cell density reaches $1 \times 10^6$/ml or $5 \times 10^6$/ml. Supporting Video S3 is the complete video showing the one-year evolution.
observed substantial therapeutic responses that cannot be simply explained by the additive effect (Supporting Fig. S4). Second, the same therapy was given to patients 2 and 3, but did not yield positive therapeutic responses (Fig. 4c and Supporting Fig. S5); patient 2 exhibited a modest benefit by one month and patient 3 almost did not respond at all. Figure 4d shows the results of a 3D stochastic simulation of cell population dynamics in response to combination therapy administered at different times. Considering that these treatments were administered at a middle to late stage when clinically detectable tumors had already developed, we conclude that the combination therapy tailored to match individual patients is more focused and can give better therapeutic benefit even when microglia depletion therapy fails in the middle to late stages, highlighting the critical need for molecular diagnosis and patient stratification prior to the design of a combination therapy that targets the tumor microenvironment.

Discussion

To the best of our knowledge, this is the first study that attempts to integrate a variety of cells and their intercellular signaling pathways into a cell-cell communication network and assess how this network controls tumor initiation and progression at the systems level. Through in silico experimentation of tumor microenvironment development, the dynamics of cells and cytokines correctly reflects general trends of tumorigenesis observed experimentally or clinically [17,51,58]. We also discovered interesting phenomena that can be seen only at the systems level and are often masked in conventional tumor biology studies.

First, the cell population dynamics obtained using a set of coupled differential equations based upon population dynamics and the Monte Carlo method yield the full time courses of all five cell types. Although significant inter-patient heterogeneity has been observed, the time courses of glioma microenvironment development for all virtual patients we encountered do share common characteristics and exhibit three-phase non-linear evolution dynamics. For example, all patients experience the pre-tumor phase; the mutual paracrine stimulation between microglial cell and glioma cell results in the continued growth of microglia. These results, obtained via in silico experimentation without fitting or optimization to any specific clinical or experimental data, were found to well reflect the general mechanisms of glioma development [17,20].

Second, soluble signaling proteins, e.g. cytokines, are the key components mediating the cell-cell communication network in a tumor microenvironment. We successfully integrated 15 cytokines in 69 paracrine/autocrine pathways in the cell population dynamics model. We further examined relative weight factors for all the paracrine/autocrine loops associated with tumor development. This study provides new insights into tumor microenvironment development and suggests that therapies targeting the cytokine-mediated intercellular signaling network in a tumor microenvironment need to be personalized.

Third, we designed a microglia depletion therapy by adding a virtual drug in the tumor to increase the microglia apoptosis rate. The observation from in silico experimentation indicates that this therapy shows some efficacy only when patients are treated at very early stages, which is consistent with the general outcomes of anti-cancer treatment, but provides a new mechanism to explain the therapeutic resistance observed in the clinic. The ineffectiveness of microglia-targeted therapy in the middle to late phases indicates the emergence of an autocrine-dominant, self-propelled glioma proliferation. Then, we moved to look for another therapy that directly targets multiple key cytokines to assess the possibility of treating glioma in the middle to late stages. It turns out a more focused combination therapy can suppress tumor growth at the middle stage when the tumor becomes clinically detectable and microglia-depletion therapy is ineffective. Further study on virtual patients reveals inter-patient heterogeneity in response to the same combination therapy, and highlights the importance of designing therapy individually tailored to the patient's tumor microenvironment. While current anti-cancer drugs mostly target tumor cells, this study indicates the possibility and quantitatively assessed the effectiveness of new therapies that target cellular or molecular components of the tumor microenvironment, pointing to completely new venues for tumor control and treatment.

In the end, a model as reported herein may serve as a tool to integrate clinical data obtained from informative molecular diagnosis of patients, predict the dynamics of tumor progression, and aid the design of personalized therapy. The technologies for such informative diagnosis are anticipated (1) to measure both tumor cells and a variety of cells in a tumor microenvironment, and (2) to analyze cytokine secretion profiles at the single-cell level such that a cytokine-mediated cell-cell communication network can be re-constructed for any individual patient. Currently, such technologies are not yet available in the clinic, but there have been significant research efforts in the past years that aim to develop single-cell proteomics technologies and clinical microchips for informative diagnosis of complex diseases including cancer [59,60,61,62],[63]. In the future, integration of such technologies and the model described here can turn into a powerful clinical tool to diagnose the tumor microenvironment and the associated intercellular signaling network in individual patients and truly enable personalized therapy by selective targeting of the tumor microenvironment.

Methods

Algorithm

While the microenvironment exerts a significant selective pressure on the tumor, the tumor cells persistently reshape their microenvironment to synergistically support the growth and spread of the tumor. The dynamically changing levels of signaling molecules that revire tumor-stromal interactions along with tumor progression will provide insights into the mechanisms of disease development.

Assumptions and model construction

Since this work is focused on predicting tumor time course evolution, the model is based, for simplicity, on a well-mixed species system. Five types of cells (quiescent and activated glioma stem/progenitor cells, glioma cells, astrocytes, and microglial cells) and 15 growth factors/cytokines/chemokines are integrated in this model. We assume that the species included in the model evolve independently of species excluded from the model (oligodendrocyte, etc.). In the end, we present the intercellular signaling network as a set of coupled ordinary differential equations in terms of population dynamics. The rates of change of cells are expressed by the conversion rate, proliferation rate, and decay rate (see Supporting Text S1).

A set of coupled stochastic ordinary differential equations describing the co-evolution of tumor microenvironment is constructed using population dynamics and stochastic dynamics. The basic mathematical model is based on continuous logistic proliferation and discrete event type fluctuation, and can be described as
The last term is the decay term with half-life $\tau = \ln 2 / \ln(2m_{\text{cell}} + \Delta)$. The third term indicates the logistic proliferation of cell $x_i$. The first term on the right-hand side of Eq. (4) quantifies the production of cytokine $y_j$ from cell $x_i$ with basic secretion rate function $k_{\text{sec}}(t)$, and the secretion is stimulated by cytokine $y_0$ and inhibited by $y_i$. The last term is the decay term with half-life $\ln 2 / \mu_j$, and can be regulated in the presence of cytokine $y_0$.

To further assess how fluctuations in biological processes reflect the random nature and affect the performance of the system, we introduce the following stochastic process interpretation of the rate parameters:

$$r_i(t) = r_i^0 \left[ 1 + \varepsilon \sin \left( \frac{2\pi m_{\text{cell}}}{\ln 2} t + \beta W(t) + \Delta \right) \right], \quad \varepsilon < 1 \quad (5)$$

$$m_{k_i}(t) = m_{k_i}^0 \left[ 1 + \varepsilon \sin \left( \frac{2\pi m_{\text{cell}}}{\ln 2} t + \beta W(t) + \Delta \right) \right], \quad 0 \leq m_{k_i}^0 \leq 1, \quad 0 \leq \varepsilon \leq \min \left( 1, \frac{1}{m_{k_i}^0} - 1 \right) \quad (6)$$

where $W(t)$ is a standard Wiener process, and $\xi(t)$ is a zero-mean Gaussian white noise with unit intensity. The sections 1 & 2 in Supporting Text S1 give a full set of deterministic ordinary differential equations (ODE) and detailed explanations of stochastic description.

The stochastic dynamics are studied using Monte Carlo simulations. The corresponding time series of the species concentration are obtained by integrating these differential equations numerically using the fourth-order Runge-Kutta scheme or the fifth-order Dormand-Prince method.

**Model calibration**

The parameters are assigned in the range over which the model output most closely matches experimental observation (Supporting Table S1). Although we calibrate the model with data from the literature, the model parameters can easily be changed to patient-specific clinical parameters as needed.

**Sensitivity analysis**

To systematically evaluate the influence of each cytokine on tumorigenesis rate, we conduct a sensitivity test, in which the sensitivity factor of cytokine $x_i$ can be calculated as

$$S_i = \frac{\hat{F}(\mathbf{x})}{\hat{F}(\mathbf{x})}$$

$$\mathbf{x} = \mathbf{x}^0 \quad (11)$$

where $F(\mathbf{x})$ is the objective function (e.g., tumorigenesis time, cell density, cytokine concentration), and $\mathbf{x}^0$ is the local parameter profile.

The results show marked effects of these cytokines on the development of glioma and suggest the possibility of designing therapeutic intervention by targeting cytokine signaling loops (both cytokine production and receptor expression level) (Supporting Fig. S6 and Table S6). The quantitative results are also found to be context specific; the exact time for observing tumor formation ($1 \times 10^6$ cells/ml) depends on the profile of all initial parameters for each virtual patient (Supporting Tables S3 and S4).

The greater the difference between cytokine sensitivity factor landscapes, the greater is the inter-patient heterogeneity. In addition to the quantitative manifestation of inter-patient heterogeneity, sensitivity analysis also points to a venue to identify a cytokine profile that potentially can serve as a molecular signature for tumor sub-classification, and thus provides a means to stratify patients via their cytokine profiles and to design individualized treatment.

**Supporting Information**

**Figure S1** Contributions of ASC differentiation and astrocyte mutation to glioma development.
Figure S2 Influence of initial conditions to tumorigenesis time. (TIF)

Figure S3 Virtual therapy of patient #3 demonstrates the difference of therapeutic efficacy between single-targeted and combination-targeted. (TIF)

Figure S4 Virtual therapies of two patients demonstrate the therapeutic efficacy of combination-targeted therapy. (TIF)

Figure S5 Three patients are treated with the same protocol, which is personalized according to the cytokine secretion profile of patient #3. (TIF)

Figure S6 Inter-patient heterogeneity was demonstrated by sensitivity analyses. (TIF)

Table S1 Deterministic parameters. (DOCX)

Table S2 Stochastic parameters. (DOCX)

Table S3 Patients parameters for Figure S5(a). (DOCX)

Table S4 Patients parameters for Figure S5(b). (DOCX)

Table S5 Parameter profiles of three virtual patients for Figure 3 and 4. (DOCX)

Table S6 The x-coordinate parameter panels for Figure S5(a). (DOCX)

Table S7 The x-coordinate parameter panels for Figure 4(a) and Figure S5(b). (DOCX)

Text S1 Section 1: Deterministic description of the intercellular signaling network. Section 2: Stochastic description of rate parameters. Section 3: Sensitivity analysis. (PDF)

Video S1 Evolution of tumor microenvironment without therapy. (MPG)

Video S2 Evolution of tumor microenvironment in patient #1 in response to microglia depletion therapy administered at glioma cell concentration 2 × 10^5/ml. (MPG)

Video S3 Evolution of tumor microenvironment in patient #1 with personalized combination therapy when the glioma cell density reaches 1 × 10^6/ml. (MPG)

Acknowledgments

We thank Dr. Jiangbing Zhou and Dr. Kathryn Miller-Jensen for helpful discussion.

Author Contributions

Conceived and designed the experiments: RF. Performed the experiments: YW. Analyzed the data: YW RF YL WC JF. Wrote the paper: RF YW.

References

1. Hanahan D, Weinberg RA (2011) Hallmarks of Cancer: The Next Generation. Cell 144: 646–674.
2. Weinberg RA (2008) Coevolution in the tumor microenvironment. Nat Genet 40: 494–495.
3. Anderson ARA, Weaver AM, Cummings PT, Quaranta V (2006) Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127: 905–915.
4. Thity TD, Cousens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol-Med 1: 119–150.
5. Polyak K, Hovie I, Campbell RG (2009) Co-evolution of tumor cells and their microenvironment. Trends Genet 25: 30–38.
6. Sawyer CL (2007) Where lies the blame for resistance - tumor or host? Nat Med 13: 1144–1145.
7. Karlos M, Tzepeli V, Elisabathou E (2010) Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 7: 494–509.
8. Joyce JA (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell 7: 513–520.
9. Hu M, Polyak K (2008) Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18: 27–34.
10. Das S, Srikanta M, Kesler JA (2000) Cancer stem cells and glioma. Nat Clin Pract Neuro 4: 427–435.
11. Furnari FB, Fenton T, Bachoo RM, Miska A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Gene 21: 2683–2710.
12. Iwasa Y, Michor F (2011) Evolutionary Dynamics of Intratumor Heterogeneity. PLoS One 6: e17066.
13. Clarke MP, Dick JE, Dubb PB, Eaves CJ, Jamieson CHM, et al. (2006) Cancer stem cell perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339–9344.
14. Bao SD, Wu QL, Sathornsumetee S, Hao YL, Li ZZ, et al. (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66: 8432–8443.
15. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396–401.
16. Reyer D, Hao P, Proescholdt M, Lohmeier A, Wischhusen J, et al. (2007) CD133(+) and CD133(−) glioblastoma-derived Cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010–4015.
17. Luo KM, Kim SY, Jin X, Song SY, Kong DS, et al. (2008) Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 88: 808–813.
18. Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, et al. (2008) Identification of A2B5(+)/CD133(-) tumor-initiating cells in adult human gliomas. Neurosurgery 62: 505–514.
19. Wang J, Sakarissian PO, Tsinikalovsky O, Immervoll H, Boe SO, et al. (2008) CD133(-) negative glioma cells form tumors in nude rats and give rise to CD133(+ ) positive cells. Int J Cancer 122: 761–768.
20. Roggendorf W, Krupp S, Paulus W (1996) Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol 92: 289–293.
21. Leung SY, Wong MP, Chung LP, Chan ASY, Yuen ST (1997) Monocyte chemotactic protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 93: 518–527.
22. Pelt E, Baron P, Meda L, Scarpin I, Galimberti D, et al. (2008) The human astrocytoma cell line U373MG produces monocyte chemotactic protein (MCP)-1 upon stimulation with beta-amyloid protein. Neurosci Lett 383: 177–180.
23. Platten M, Kretz A, Naumann U, Aulwurm S, Egharda K, et al. (2003) Monocyte chemotactic protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 54: 388–392.
24. Galasso JM, Stegman LD, Blaivas M, Harrison JR, Ross BD, et al. (2000) Experimental gliosarcoma induces chemokine receptor expression in rat brain. Exp Neurol 161: 85–95.
25. Huttner B, Czup S, Kerka S, Roggendorf W, Tonn JC (1997) Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 17: 3217–3224.
26. Badie B, Schartner J (2001) Role of microglia in glioma biology. Microsc Res Techniq 54: 106–113.
27. Betteing J, Thanes S, Paulus W (2002) Microglia promote glioma migration. Acta Neuropathol 103: 351–355.
28. Giudian D, Baker TJ (1986) Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci 6: 2163–2178.
29. Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E (1982) Production of prostaglandin-e and an interleukin-1 like factor by cultured astrocytes and c6 glioma-cells. Lab Invest 46: 1201–1213.
30. Paugh BS, Bryan L, Paugh SW, Wilczynska KM, Alvarez SM, et al. (2009) Interleukin-1 regulates the Expression of Sphingosine Kinase 1 in Glioblastoma Cells. J Biol Chem 284: 3408–3417.
31. Tada M, Detribolet N (1993) Recent advances in immunobiology of brain-tumors. J Neuro-Oncol 17: 261–271.
41. Lucas B, Edelman JAE, Nathan DPrice (2010) In silico models of cancer. Wiley Interdiscip Rev - Syst Biol 2: 438–459.
42. Waters JJ, Scharitter JM, Badie B (2005) Microglia function in brain tumors. J Neurosci Res 81: 447–455.
43. Graeber MB, Scheithauer BW, Kreutzberg GW (2002) Microglia in brain tumors. Glia 40: 252–259.
44. Fan XL, Salford LG, Widgren B (2007) Glioma stem cells: Evidence and limitation. Semin Cancer Biol 17: 214–218.
45. Holland EC, Hively WP, DePinho RA, Varmus HE (1998) A constitutively active epidermal growth factor receptor cooperates with disruption of G1-cell-cycle arrest pathways to induce glioma-like lesions in mice. Gene Dev 12: 3673–3685.
46. Jellinger K (1978) Glioblastoma multiforme - morphology and biology. Acta Neurochir 42: 5–32.
47. Hatten ME (1985) Neuronal regulation of astroglial morphology and proliferation invitro. J Cell Biol 100: 384–396.
48. Schiefer H, Rowley DA (2010) Awakening Immunity. Science 330: 761–762.
49. Xie Q, Thompson R, Hardy K, DeCamp L, Berghuis B, et al. (2008) A highly invasive human glioblastoma pre-clinical model for testing therapeutic. J Transl Med 6: 77.
50. Schreiber H, Rowley DA (2010) Awakening Immunity. Science 330: 761–762.
51. Laws ER, Jr., eds. Brain tumors: An encyclopedic approach. Edinburgh: Churchill Livingstone. pp 125–162.
52. Stoker MGP, Rubin H (1967) Density dependent inhibition of cell growth in tissue culture. Nature 215: 171–&.
53. Lopes MBS, Vandenbroucke SR, Scheithauer BW (1993) Histopathology, immunohistochemistry and ultrastructure of brain tumors. In: Kaye AH, Laws ER, Jr., eds. Brain tumors: An encyclopedic approach. Edinburgh: Churchill Livingstone. pp 125–162.
54. McKnight TR, Lamborn KR, Love TD, Berger MS, Chang S, et al. (2007) Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg 106: 660–666.
55. Marumoto T, Tashiro A, Friedmann-Morvinski D, Scaleg M, Souda Y, et al. (2009) Development of a novel mouse glioma model using lentiviral vectors. Nat Med 15: 110–116.
56. Lee SC, Liu W, Dickson DW, Broman CF, Berman JW (1993) Cytokine production by human fetal microglia and astrocytes - differential induction by lipopolysaccharide and IL-1-beta. J Immunol 150: 2659–2667.
57. Wu M, Pastor-Pareja JG, Xu T (2010) Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion. Nature 463: 545–U165.
58. Takane S, Yoshii S, Kondo S, Suzuki H, Maruno T, et al. (1996) Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56: 2185–2190.
59. Irish JM, Kotecha N, Nolan GP (2006) Innovation - Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 6: 146–155.
60. Xu B, Du W, Liu BF, Luo QM (2008) Single cell proteomics: Challenge for current analytical science. Curr Anal Chem 2: 67–78.
61. Huang B, Wu HK, Bhaya D, Grossman A, Granier S, et al. (2007) Counting low-copy number proteins in a single cell. Science 315: 81–84.
62. Kotecha N, Flores NS, Irish JM, Simonds EF, Sakai DS, et al. (2008) Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14: 335–343.
63. Ma C, Fan R, Ahnaf H, Shi Q, Comin-Anduix B, et al. (2011) A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med 17: 738–U133.